Jan 8 (Reuters) - CorMedix Inc CRMD.O:

• CORMEDIX THERAPEUTICS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025 RESULTS AND PROVIDES BUSINESS UPDATES

• Q4 2025 UNAUDITED NET REVENUE ABOUT $127 MILLION

• EXPECTS Q4 ADJUSTED EBITDA BETWEEN $77 MILLION AND $81 MILLION

• INTRODUCES FY 2026 REVENUE GUIDANCE $300-$320 MILLION

• ESTIMATES FULL-YEAR 2027 DEFENCATH SALES IN RANGE OF $100 MILLION TO $140 MILLION

• SEE FY 2026 OPERATING EXPENSES OF $145 MILLION TO $160 MILLION, EXCLUDING NON-CASH ITEMS AND ONE-TIME EXPENSES

• ESTIMATES FY 2026 ADJUSTED EBITDA IN RANGE OF $100 MILLION TO $125 MILLION

• FY2026 REVENUE VIEW $437.3 MILLION -- LSEG IBES DATA

• Q4 REVENUE VIEW $127.5 MILLION -- LSEG IBES DATA

Source text: ID:nGNXc43vHb

Further company coverage: CRMD.O

((Reuters.Briefs@thomsonreuters.com;))